This has necessitated that studies on ALDH1A3 be performed in immune-deficient models where the paracrine effects of tumor-derived atRA would not be identified, thus explaining why a clear mechanism of ALDH1A3 has not yet been identified in cancer. This evidence concerns the gene ALDH1A3 and neoplasm.